BioSpark Competition
The 2026 Finalists
Eight companies were selected from the 2026 application pool. Each is pre-seed or seed stage, holds full ownership of its technology, and has raised no more than $10 million to date.
3D OrthoBiologic Solutions (3DOS)
Customized, 3D-printed bone grafts that help surgeons repair and regenerate bone lost to cancer, disease, or trauma.
AVIL Therapeutics
A first-in-class targeted small molecule for glioblastoma, built on AVIL, a novel oncogene discovered at the University of Virginia.
Claradele Pharmaceuticals
PMJ2, a first-in-class small-molecule immunotherapy that restores checkpoint inhibitor sensitivity in cold, treatment-resistant melanoma.
NeoSplice Therapeutics
Cancer-specific splice variants and proteoforms as drug targets, resolved with long-read sequencing, single-cell isoform profiling, and proteogenomic mass spectrometry.
Oridivus
Locally delivered therapeutic matrices for oral and maxillofacial wound healing, giving clinicians a purpose-built way to control post-operative inflammation and pain.
Sensible
A women-led team building a patent-pending menstrual biomarker platform that turns menstrual blood into longitudinal health insights through a non-invasive wearable.
SonoFx
Tissue-integrating regenerative biomaterials and a simplified delivery device for vocal fold paralysis and glottic insufficiency.
Visurraga Enterprises
Fibreye, an AI-powered airway intelligence platform that turns endotracheal intubation from passive visualization into intelligent navigation.
2026 Results
- 1st Place: NeoSplice Therapeutics
- 2nd Place: 3D OrthoBiologic Solutions (3DOS)
- Commonwealth BioAccelerator Residency: Oridivus
The 2026 BioSpark Judges
- Sara Dauber, Vice President, JP Morgan
- Gabe Gutierrez, Innovation Manager, University of Maryland Ventures
- Deanna Angello, Founder and President, Alpenglow Ventures LLC
- Matt Schwee, Partner, Cooley
